Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Oct 21;8(10):440.
doi: 10.3390/biomedicines8100440.

Modelling C9orf72-Related Amyotrophic Lateral Sclerosis in Zebrafish

Gabrielle Fortier  1 , Zoé Butti  1 , Shunmoogum A Patten  1   2
Affiliations
Review

Modelling C9orf72-Related Amyotrophic Lateral Sclerosis in Zebrafish

Gabrielle Fortier et al. Biomedicines. .

Abstract

A hexanucleotide repeat expansion within the C9orf72 gene is the most common genetic cause of amyotrophic lateral sclerosis (ALS) and its discovery has revolutionized our understanding of this devastating disease. Model systems are a valuable tool for studying ALS pathobiology and potential therapies. The zebrafish (Danio rerio) has particularly become a useful model organism to study neurological diseases, including ALS, due to high genetic and physiological homology to mammals, and sensitivity to various genetic and pharmacological manipulations. In this review we summarize the zebrafish models that have been used to study the pathology of C9orf72-related ALS. We discuss their value in providing mechanistic insights and their potential use for drug discovery.

Keywords: ALS; C9orf72; motoneuron; zebrafish.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Kiernan M.C., Vucic S., Cheah B.C., Turner M.R., Eisen A., Hardiman O., Burrell J.R., Zoing M.C. Amyotrophic lateral sclerosis. Lancet. 2011;377:942–955. doi: 10.1016/S0140-6736(10)61156-7. - DOI - PubMed
    1. Brown R.H., Al-Chalabi A. Amyotrophic Lateral Sclerosis. N. Engl. J. Med. 2017;377:162–172. doi: 10.1056/NEJMra1603471. - DOI - PubMed
    1. Bensimon G., Lacomblez L., Meininger V., Bouche P., Delwaide C., Couratier P., Blin O., Viader F., Peyrostpaul H., David J., et al. A Controlled Trial of Riluzole in Amyotrophic-Lateral-Sclerosis. N. Engl. J. Med. 1994;330:585–591. doi: 10.1056/NEJM199403033300901. - DOI - PubMed
    1. Abe K., Itoyama Y., Sobue G., Tsuji S., Aoki M., Doyu M., Hamada C., Kondo K., Yoneoka T., Akimoto M., et al. Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients. Amyotroph. Lateral Scler. Front. Degener. 2014;15:610–617. doi: 10.3109/21678421.2014.959024. - DOI - PMC - PubMed
    1. Pasinelli P., Brown R.H. Molecular biology of amyotrophic lateral sclerosis: Insights from genetics. Nat. Rev. Neurosci. 2006;7:710–723. doi: 10.1038/nrn1971. - DOI - PubMed

LinkOut - more resources